Isturisa

Chemical Nameosilodrostat
Dosage FormTablets (oral; 1 mg, 5 mg, 10 mg)
Drug ClassInhibitors
SystemEndocrine
CompanyRecordati Rare Disease, Inc.
Approval Year2020

Indication

  • Indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Isturisa (osilodrostat) Prescribing Information.2020Recordati Rare Disease, Inc. Lebanon, NJ